Clinical trials: Melanoma Stage
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
This phase II clinical trial studies how well thermal ablation and spine stereotactic radiosurgery work in treating patients with cancer that has spread to the spine (spine metastases) and is at risk for compressing the spinal…
- Conditions
- Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine
- Trial name
- NCT02713269
- Testing
- Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma
The goal of this clinical research study is to find the highest tolerable dose of Abraxane (nab-paclitaxel) when given in combination with cisplatin, Temodar (temozolomide), interferon alfa-2b, and interleukin-2 (IL-2) to…
- Trial name
- BCAA (NCT00970996)
- Testing
- Temozolomide, Abraxane, Cisplatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Melanoma, Stage IV Melanoma
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
This phase II trial is studying how well giving carboplatin and paclitaxel together with bevacizumab works in treating patients with stage IV melanoma that cannot be removed by surgery.
- Trial name
- NCT00255762
- Testing
- carboplatin, paclitaxel, bevacizumab
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Malignant Melanoma
Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer
The trial is conducted in Europe. This trial aims for a comparison of the pathology in lymph nodes before and after the effect of recombinant interleukin-21 in patients with stage III melanoma
- Trial name
- NCT00601861
- Testing
- recombinant interleukin-21
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- Novo Nordisk A/S
Advanced Melanoma
A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma
This is an open-label, single center, non-randomized, dose escalation phase I trial to evaluate safety and tolerability of SHR-1210 (camrelizumab) in patients with advanced melanoma with disease progression after standard…
- Trial name
- NCT02738489
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Malignancies
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this first-in-human study of MBG453 was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v.
- Trial name
- NCT02608268
- Testing
- MBG453, PDR001, Decitabine
- Where
- 14 sites in United States, Canada and 7 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma (Skin)
Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy, such as dacarbazine and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00072124
- Testing
- cisplatin, dacarbazine, conventional surgery
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from a patient's dendritic cells may make the body build an immune response to kill tumor cells. It is not yet known whether combining vaccine therapy with either gp100 antigen or the patient's tumor…
- Trial name
- NCT00085397
- Testing
- autologous dendritic cell-tumor fusion vaccine, gp100 antigen, therapeutic autologous dendritic cells
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Refractory Cancer, Recurrent Cancer
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma…
- Conditions
- Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
- Trial name
- ACTengine (NCT03686124)
- Testing
- IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product
- Where
- 21 sites in United States, Germany
- Volunteers
- 375 people
- Sponsor
- Immatics US, Inc.
Advanced Solid Tumors
A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
This is a multicenter, open-label, Phase 1b/2 study which will be conducted in two parts: a Phase 1b part comprising a dose escalation and an expansion cohort; and a Phase 2 part which will comprise two cohorts.
- Trial name
- NCT01433991
- Testing
- Golvatinib, Lenvatinib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Eisai Inc.
Melanoma Stage III, Melanoma Stage IV
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV
- Trial name
- NCT04305145
- Testing
- Infliximab, Methylprednisolone, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
Melanoma
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.
- Trial name
- NCT00429312
- Testing
- JX-594
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Jennerex Biotherapeutics
Stage III Melanoma
Interferon Toxicities in Melanoma Treatment
The primary objective of this study is to quantify and compare the prevalence of adverse events (AEs) in patients with stage III melanoma before and after initiation of interferon (IFN) therapy in a real-world setting.
- Trial name
- ITMT (NCT02794636)
- Volunteers
- 436 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer, Lung Cancer
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
This study provides an early evaluation of an entirely new class of small molecule agents directed at disruption or elimination of tumor tolerance, a phenomenon now demonstrated to be involved in the growth of many solid tumors.
- Conditions
- Breast Cancer, Lung Cancer, Melanoma, Pancreatic Cancer
- Trial name
- D-1MT (NCT00739609)
- Testing
- 1-methyl-D-tryptophan
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- NewLink Genetics Corporation
Extraocular Extension Melanoma, Recurrent Intraocular Melanoma
Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 may be a more effective treatment for metastatic melanoma of the eye.
- Trial name
- NCT00020475
- Testing
- gp100 antigen, interleukin-2, MART-1 antigen
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
The purpose of this research study is to see if the combination of HSPPC-96 and ipilimumab is safe and effective in the treatment of advanced melanoma.
- Trial name
- NCT02452281
- Testing
- ipilimumab, HSPPC-96
- Where
- United States
- Sponsor
- Rabih Said
Neoplasms, Melanoma
Study of ASN003 in Subjects With Advanced Solid Tumors
The study is divided into two parts. The first part of the study will test various doses of ASN003 to find out the highest safe dose to test in three specific groups.
- Conditions
- Neoplasms, Melanoma, Colorectal Neoplasm, Carcinoma, Non-small Cell Lung
- Trial name
- NCT02961283
- Testing
- ASN003 ascending doses, ASN003 MTD
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Asana BioSciences
Melanoma
Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)
The purpose of this study is to see if the proposed therapy will delay or stop the progression of the participants skin cancer. This study is being done because there are currently no treatments which have been shown convincing…
- Trial name
- NCT00809588
- Testing
- Autologous, lethally irradiated melanoma cells
- Where
- 2 sites in United States
- Volunteers
- 84 people
- Sponsor
- Dana-Farber Cancer Institute
Malignant Melanoma
ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases
This is a Phase 2 multicenter, open label, non-randomized, interventional study enrolling 53 patients.The objectives and purposes of the clinical study described herein are to determine if concomitant Pembrolizumab (Keytruda) and…
- Trial name
- NCT03448666
- Testing
- Pembrolizumab
- Where
- Italy
- Sponsor
- European Institute of Oncology
Malignant Melanoma
A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)
This is a study to evaluate the safety and tolerability of peginterferon alfa-2b (PegIFN alfa-2b) as adjuvant treatment in Japanese participants with malignant melanoma after definitive surgical resection including complete…
- Trial name
- NCT01636960
- Testing
- PegIFN alfa-2b
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.